IGC Pharma为其实验性阿尔茨海默氏病药物IGC-AD1获得美国和加拿大专利保护,这是朝发展和潜在市场启动迈出的重要一步。 IGC Pharma gained U.S. and Canadian patent protection for its experimental Alzheimer’s drug IGC-AD1, a major step toward development and potential market launch.

IGC Pharma在北美为其实验性阿尔茨海默氏病药物IGC-AD1(IGC-AD1)建立了物质构成保护,这是扩大该化合物专属性的关键里程碑。 IGC Pharma has secured composition-of-matter protection in North America for its experimental Alzheimer’s drug IGC-AD1, a key milestone that extends exclusivity for the compound. 该公司还在推进CALMA第二阶段试验的注册率,该试验正在评价该药物在早期阿尔茨海默氏病患者的认知下降速度方面减慢的潜力。 The company is also advancing enrollment in the Phase 2 CALMA trial, which is evaluating the drug’s potential to slow cognitive decline in early Alzheimer’s patients. 保护包括IGC-AD1的具体分子结构,支持进一步发展和可能的商业化。 The protection covers the specific molecular structure of IGC-AD1, supporting further development and potential commercialization.